Vaxcyte, Inc. PCVX
60.55 USD -0.07 (-0.12%)
Nov 3, 2026, 3:48 PM EST
60.32 Day range 61.89
39.87 52-week range 90.75
- YTD
- +31.23%
- 1 year
- +41.37%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 117.30 +93.7% upside
Now 60.55
- Target (low)
- 75.00
- Target (mean)
- 117.30
- Target (high)
- 163.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy1
- Buy9
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -2.11 | -2.68 – -1.67 | -1.56 | -35.3% | 0 | 0.0% | 7 |
| Next quarter | -1.96 | -2.69 – -0.86 | -1.80 | -9.0% | 0 | 0.0% | 7 |
| Current year | -8.14 | -9.66 – -6.19 | -5.63 | -44.6% | 0 | 0.0% | 7 |
| Next year | -7.12 | -11.42 – -4.96 | -8.14 | +12.6% | 87.15M | 0.0% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Oct 5, 2026 | BTIG | Reiterated | Buy | Buy |
| Oct 5, 2026 | Needham | Maintained | Buy | Buy |
| Oct 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 28, 2026 | B of A Securities | Maintained | Buy | Buy |
| Sep 25, 2026 | Needham | Reiterated | Buy | Buy |
| Feb 26, 2026 | BTIG | Maintained | Buy | Buy |
| Feb 2, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Nov 10, 2025 | BTIG | Reiterated | Buy | Buy |
| Oct 16, 2025 | BTIG | Maintained | Buy | Buy |
| Sep 12, 2025 | Goldman Sachs | Initiated | — | Neutral |
| Apr 22, 2025 | Cantor Fitzgerald | Initiated | — | Overweight |
| Apr 8, 2025 | Needham | Reiterated | Buy | Buy |
| Apr 1, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Apr 1, 2025 | B of A Securities | Maintained | Buy | Buy |
| Apr 1, 2025 | Needham | Maintained | Buy | Buy |
| Mar 12, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 26, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 26, 2025 | Needham | Reiterated | Buy | Buy |
| Feb 24, 2025 | BTIG | Reiterated | Buy | Buy |
| Feb 11, 2025 | Needham | Reiterated | Buy | Buy |
| Dec 24, 2024 | BTIG | Reiterated | Buy | Buy |
| Dec 20, 2024 | Goldman Sachs | Initiated | — | Buy |
| Nov 6, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Nov 6, 2024 | Needham | Reiterated | Buy | Buy |
| Sep 10, 2024 | Mizuho | Maintained | Outperform | Outperform |
| Sep 4, 2024 | B of A Securities | Maintained | Buy | Buy |
| Sep 3, 2024 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 3, 2024 | Jefferies | Maintained | Buy | Buy |
| Sep 3, 2024 | Needham | Maintained | Buy | Buy |